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incidence. The mutation c.4183C>T was detected in 30.4% of hereditary BRCA1-associated breast and
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negative) Tyrolean breast cancer patients and 6.8% of unselected ovarian cancer patients from the Lower
Inn Valley (LIV) region. Cancer incidences showed a region-specific increase in age-stratified breast and
ovarian cancer risk with standardized incidence ratios of 1.23 and 2.13, respectively. We, thus, report a
Tyrolean BRCA1 founder mutation that correlates to a local increase in the breast and ovarian cancer
risks. On the basis of its high prevalence, we suggest that targeted genetic analysis should be offered to
all women with breast or ovarian cancer and ancestry from the LIV region.
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ARTICLE
High prevalence of BRCA1 stop mutation c.4183C4T
in the Tyrolean population: implications for genetic
testing
Laura Pölsler1,7, Heidi Fiegl2,7, Katharina Wimmer1, Willi Oberaigner3,4, Albert Amberger1, Pia Traunfellner1,
Raphael J Morscher1,5, Ingrid Weber1, Christine Fauth1, Annekatrin Wernstedt1, Barbara Sperner-Unterweger6,
Anne Oberguggenberger6, Michael Hubalek2, Christian Marth2 and Johannes Zschocke*,1
Screening for founder mutations in BRCA1 and BRCA2 has been discussed as a cost-effective testing strategy in certain
populations. In this study, comprehensive BRCA1 and BRCA2 testing was performed in a routine diagnostic setting. The
prevalence of the BRCA1 stop mutation c.4183C4T, p.(Gln1395Ter), was determined in unselected breast and ovarian cancer
patients from different regions in the Tyrol. Cancer registry data were used to evaluate the impact of this mutation on regional
cancer incidence. The mutation c.4183C4T was detected in 30.4% of hereditary BRCA1-associated breast and ovarian cancer
patients in our cohort. It was also identiﬁed in 4.1% of unselected (26% of unselected triple negative) Tyrolean breast cancer
patients and 6.8% of unselected ovarian cancer patients from the Lower Inn Valley (LIV) region. Cancer incidences showed a
region-speciﬁc increase in age-stratiﬁed breast and ovarian cancer risk with standardized incidence ratios of 1.23 and 2.13,
respectively. We, thus, report a Tyrolean BRCA1 founder mutation that correlates to a local increase in the breast and ovarian
cancer risks. On the basis of its high prevalence, we suggest that targeted genetic analysis should be offered to all women with
breast or ovarian cancer and ancestry from the LIV region.
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INTRODUCTION
A central aim of preventive oncology is the identiﬁcation of patients
with a heritable predisposition to cancer. An estimated 1–7% of
unselected breast cancer patients1–4 and 6–17% of women with ovarian
cancer5,6 have hereditary breast and ovarian cancer (HBOC) disposi-
tion caused by variants in either BRCA1 or BRCA2 that confer a high
risk of developing cancer. In agreement with a widely used terminology,
such variants will be called mutations throughout this paper. Because
of high costs, comprehensive molecular analyses for HBOC are usually
restricted to individuals with a suggestive family history, young age, or
several independent tumours. Tumour characteristics (triple-negative
breast cancer; TNBC) are also used for the identiﬁcation of patients
with a high probability of carrying a BRCA mutation.7,8
Reduced costs of novel sequencing methods and better knowledge
of the clinical relevance of alterations in BRCA1 and BRCA2 will
increase the number of individuals eligible for sequence analysis,
although some selection process will still remain necessary in the
foreseeable future. Identiﬁcation of common founder mutations in
certain ethnicities allows integration of genetic testing strategies in the
routine care of all cancer patients. Here we report the identiﬁcation of
a highly prevalent BRCA1 founder mutation in a particular region of
the Tyrol and consider the implications for a screening programme
offered to all breast and ovarian cancer patients in this region.
MATERIALS AND METHODS
Patients
The diagnostic cohort of this report consists of 238 apparently independent
index individuals. Details are described in Supplementary Information.
Presence of BRCA1 stop mutation c.4183C4T was investigated in tumour
samples from a research cohort of unselected Tyrolean individuals with breast
cancer (n= 471) and ovarian cancer (n= 186). Details are described in
Supplementary Table S1. Breast and ovarian cancer samples were selected to
fall each into two matching sub-groups based on patients’ home address: one
sub-group comprised 219 breast and 59 ovarian cancer patients from the Lower
Inn Valley (LIV) region (districts Schwaz and Kufstein). The other sub-group
included 250 breast and 125 ovarian cancer patients from other districts of the
North Tyrol. Number of analysed cases according to the districts can be seen in
Figures 1a and b.
The study was approved by the Ethics Committee of the Medical University
Innsbruck (reference number: UN4848).
A detailed version of Materials and Methods can be found in Supplementary
Information and Supplementary Table S2.
RESULTS
Identiﬁcation of a Tyrolean BRCA1 founder mutation
BRCA1 and BRCA2 mutations were identiﬁed in 70 index individuals
from 238 seemingly unrelated families with suspected HBOC (29.4%).
Forty-six index patients (65.7%) carried 21 different BRCA1 mutations
and 24 patients (34.3%) carried 23 different BRCA2 mutations
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(Supplementary Table S3). The same BRCA1 mutation NM_007294.2:
c.4183C4T was identiﬁed in 14 seemingly unrelated families, represent-
ing 30.4% of BRCA1-associated HBOC families in our cohort (cases of
ovarian/lower abdominal cancer were reported in 8/13 families for which
information was available). Evaluation of the regional origin of these
families revealed that 11 of them were from the LIV region, with the
majority from the Zillertal, a large connected side valley of this region.
Assessment of sequencing data in informative c.4183C4T mutation
carriers showed that with the exception of a patient from Germany, all
13 c.4183C4T mutation carriers from the Tyrol had SNV genotypes
compatible with a haplotype described as B1 allele by Frosk et al.9
Genotyping of all 13 Tyrolean c.4183C4T mutation carriers in the
diagnostic cohort was compatible with a common haplotype c.[2082 T;
2311C; 2612 T; 3113G]; D17S1323[171]; D17S1322[136]; D17S855[145]
on one allele. Segregation analysis in three informative families
conﬁrmed this haplotype on the mutant allele (data not shown).
High prevalence of BRCA1 mutation c.4183C4T in unselected
Tyrolean breast and ovarian cancer patients
More than 75% (11/14) of molecularly conﬁrmed HBOC families from
the LIV region carried the founder mutation c.4183C4T. To assess the
prevalence of this mutation in a larger number of individuals, we
examined a total of 219 breast and 59 ovarian cancer samples from
unselected patients living in that region. Mutation frequencies were
compared with matching breast (n= 250) and ovarian (n= 125) cancer
Figure 1 (a) Number and distribution of breast cancer cases genotyped for the BRCA1 mutation c.4183C4T in the North Tyrol. (b) Number and distribution of
ovarian cancer cases genotyped for the BRCA1 mutation c.4183C4T in the North Tyrol. Grey outline: the Austrian federal state of the Tyrol; red outline: the Lower
Inn Valley region (districts Schwaz and Kufstein). Filled parts of circles: number of cases without the mutation. Hatched parts of circles: number of mutation carriers.
Table 1 Breast and ovarian cancer incidence and risk by geographic
region
Cases observed SIR age standardized Cumulative risk
Breast cancer risk (o50)
LIV-Z 59 1.23 (0.93–1.58) 1 in 46
LIV-M 260 1.05 (0.93–1.19) 1 in 53
North Tyrol 915 1 1 in 57
Ovarian cancer risk (o65)
LIV-Z 19 2.13 (1.29–3.33) 1 in 99
LIV-M 74 1.34 (1.05–1.69) 1 in 146
North Tyrol 230 1 1 in 198
Abbreviations: LIV-Z, Zillertal; LIV-M, Lower Inn Valley excluding the Zillertal; SIR, standardized
incidence ratio.
95% conﬁdence interval is given in brackets. Signiﬁcant values in bold.
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Table 2 Comparison of BRCA1 c.4183C4T mutation carriers and non-carriers from the Lower Inn Valley region
Non-carriers (n=210) BRCA1 c.4183C4T carriers (n=9) P-valuea
A. Breast cancer patients
Patient age at diagnosis (years)
Median 56.7 41.0 0.002
Range 29.5–84.0 22.3–65.7
Sample age (years)
Median 4.8 3.9 NS
Range 1.4–11.1 2.3–7.0
Tumour grade





Invasive lobular carcinoma 1 0 NS
Invasive ductalcarcinoma 151 7
Mixed: invasive ductalcarcinoma and DCIS 54 1
Medullary carcinoma 4 1
MP
















Neg (triple-negative tumours) 20 7 o0.001
Pos 190 2
Unknown 0 0
Non-carriers (n=55) BRCA1 c.4183C4T carriers (n=4) P-valuea
B. Ovarian cancer patients
Patient age at diagnosis (years)
Median 59.1 56.7 NS
Range 39.5–84.1 50.3–62.4
Sample age (years)
Median 7.9 11.0 NS
Range 1.4–13.8 8.8–13.9
FIGO





Abbreviations: Neg, negative; NS, not signiﬁcant; Pos, positive. Bold P-values are signiﬁcant at the 0.05 level.
aThe χ2-test was used for testing associations between clinicopathological features and the mutation status and the Mann–Whitney U-test was used for the analysis of associations between the age
and the mutation status.
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samples from patients living in other regions of the Tyrol. Although the
mutation was detected in 4.1% (9/219) of breast cancer and 6.8%
(4/59) of ovarian cancer samples from patients of the LIV, it was absent
in all other Tyrolean samples (Figures 1a and b). This difference was
highly signiﬁcant (P= 0.001, respectively, P= 0.011, using χ2-test). SNV
genotyping in all tumours with the BRCA1 mutation c.4183C4T was
compatible with at least one B-allele present.
Increased breast and ovarian cancer incidence in regions with a
high prevalence of BRCA1 mutation c.4183C4T
Considering that the majority of known families with the BRCA1
c.4183C4T mutation originate from the Zillertal, we subdivided the
LIV region into the Zillertal (denoted LIV-Z) and the main LIV
(denoted LIV-M) for statistical analysis of breast and ovarian cancer
incidence. Age-stratiﬁed evaluation of data from the Tyrolean Cancer
Registry based on incidence data from 2001 to 2010 revealed
incremental incidence numbers of breast and ovarian cancer from
the North Tyrol to LIV-M and LIV-Z (Table 1). The risk increase did
not meet statistical signiﬁcance for breast cancer, with an age-adjusted
SIR of 1.05 (0.93–1.19) in LIV-M (only marginal increase) and 1.23
(0.93–1.58) in the Zillertal region (LIV-Z). Age-adjusted SIR for
ovarian cancer below 65 years was signiﬁcantly increased in both, LIV-
M with a SIR of 1.34 (1.05–1.69) and LIV-Z with a SIR of 2.13 (1.29–
3.33). Notably, women from the Zillertal below the age of 65 years had
a cumulative risk of 1 in 99 for ovarian cancer and thus were twice as
likely to be diagnosed with ovarian cancer than women of this age
group in the North Tyrol outside the LIV region (1 in 198).
Clinical and tumour characteristics in BRCA1 c.4183C4T mutation
carriers
There were no signiﬁcant differences in clinical and tumour char-
acteristics between the breast or ovarian cancer research cohorts from
the LIV and the other Tyrolean regions (Supplementary Table S1).
Clinicopathological features of LIV patients with and without the
BRCA1 mutation c.4183C4T are shown in Table 2. The mutation
was identiﬁed in 16.7% (7/42) and 15.1% (8/53) of oestrogen or
progesterone receptor negative tumours, respectively. The majority
of breast cancers from c.4183C4T mutation carriers were triple-
negative tumours (7/9); vice versa, the mutation was detected in
7 out of 27 triple-negative tumours (25.9%). TNBC in a patient
from the LIV was calculated to predict the BRCA1 founder
mutation with a sensitivity of 77.8% and a speciﬁcity of 90.5%
(Pearson’s χ2-test: Po0.0001).
DISCUSSION
We identiﬁed BRCA1 or BRCA2 mutations in 30% of families at
risk for HBOC, with a BRCA1:BRCA2 ratio of 1.9:1. Six truncating
mutations have not been published previously (Supplementary
Table S3). Three alterations listed as mutations are classiﬁed as
variants of unknown signiﬁcance in the Breast Cancer Information
Core database.10 Nevertheless, there is strong evidence to consider
them as deleterious; see Supplementary Table S3.
The BRCA1 mutations c.3018_3021delTTCA and c.4183C4T were
the most frequent mutations, found seven and 14 times, respectively.
Mutation c.3018_3021delTTCA has been previously reported as an
Austrian founder mutation11 but is infrequent in persons of Tyrolean
origin.
The BRCA1 mutation c.4183C4T represented 30.4% of all
identiﬁed BRCA1 mutation alleles in our cohort. This recurrent
mutation4 is recorded in several databases10,12,13 and has been
previously observed in Austria, albeit with lower frequencies than in
our cohort.11,14 We found this mutation only in individuals who lived
in the Tyrol, an alpine province characterized by conﬁned valleys
separated by huge mountain ranges historically forming isolates.
Intriguingly, the c.4183C4T mutation was responsible for 475%
of seemingly unrelated HBOC families in the LIV region, and in
particular the major side valley Zillertal.
The high frequency and relatively restricted geographic origin of
c.4183C4T mutation carriers in our diagnostic patients suggested a
regional founder effect that was supported by a common haplotype
shared among all Tyrolean c.4183C4T carriers. To further substanti-
ate this assumption, we determined the prevalence of the BRCA1
mutation c.4183C4T in unselected breast and ovarian cancer samples
from different Tyrolean regions. The mutation was found in 4% of
breast and 7% of ovarian cancer samples from the LIV region but was
not detected in samples from other regions of the Tyrol. The highest
prevalence was found in patients from the Zillertal, conﬁrming the
observation in our diagnostic cohort. Even considering the common
mutation only, breast cancer patients from the LIV have a much
higher probability of being affected by HBOC than patients in other
regions. Comprehensive analysis of BRCA1 in unselected breast cancer
cohorts found mutation prevalence rates of 0.7–1.3% in British
studies1,2 and 3.3% in a US-based study.3 Twenty-six percentage of
breast cancer patients with TNBC from the LIV region and 50% of
patients from the Zillertal carried the BRCA1 mutation c.4183C4T.
This is a much higher percentage than the 10–20% seen in other
studies of patients with TNBC unselected for family history.7,8,15
Considering the results from both our diagnostic and research
cohorts, we wondered whether the high prevalence of mutation
c.4183C4T in the Zillertal and LIV region is associated with an
increased incidence of cancer. Detailed regional data from the
Tyrolean Cancer Registry conﬁrmed an increased risk for breast and
ovarian cancer especially in the region of Zillertal with SIRs of 1.23 for
breast cancer below the age of 50 and 2.13 years for ovarian cancer
below the age of 65 years.
Our data suggest that HBOC due to the prevalent founder mutation
c.4183C4T is an important health problem in breast and ovarian
cancer patients and their families from the LIV and should be
addressed in the care of patients from this region. Prompt and cost
efﬁcient mutation identiﬁcation is becoming clinically highly relevant
and will increasingly be so, considering the trend towards individua-
lised tumour therapy such as PARP inhibitors.16,17 Ancestry-informed
testing of a few common BRCA1/2 mutations has been proposed as a
cost-effective approach in a number of populations including Ashke-
nazi Jews.18–25 Diagnosing BRCA mutations triggers preventive
measures in relatives, which contributes to the value of such screening
approaches.21 The identiﬁcation of a prevalent founder mutation in a
very speciﬁc part of the Tyrol may facilitate a long-term study to
examine the true sensitivity, usefulness, and cost-effectiveness of
routine testing of breast or ovarian cancer patients without any
selection based on established HBOC criteria.
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